The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 26, 2021

Filed:

Dec. 22, 2016
Applicants:

Medigene Immunotherapies Gmbh, Planegg-Martinsried, DE;

Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh), Neuherberg, DE;

Inventors:

Slavoljub Milosevic, Munich, DE;

Christian Ellinger, Munich, DE;

Carina Wehner, Munich, DE;

Dolores Schendel, Munich, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 5/0784 (2010.01); A61K 38/00 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4748 (2013.01); A61K 35/17 (2013.01); A61K 38/00 (2013.01); A61K 39/001191 (2018.08); A61P 35/00 (2018.01); C12N 5/0638 (2013.01); C12N 5/0639 (2013.01); A61K 39/001184 (2018.08); A61K 2039/5154 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/06 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/24 (2013.01); C12N 2502/1114 (2013.01); C12N 2506/115 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.


Find Patent Forward Citations

Loading…